Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
Phase 4
- Conditions
- Schizophrenia or Schizoaffective Disorder
- Interventions
- Drug: Antipsychotics
- Registration Number
- NCT01016145
- Lead Sponsor
- University of Sao Paulo
- Brief Summary
The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile. Two groups of treatment will be compared: first generation antipsychotics vs. second generation antipsychotics. Participants will be randomized to one of the groups. Trial duration: 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
- Schizophrenia or schizoaffective disorder
- Age: 18-45 years olde
- Less than 10 years of diagnosis
- Acute exacerbation of psychotic symptoms
Exclusion Criteria
- Use of clozapine
- Clinical unstable disease
- Delirium and cognitive disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Second generation antipsychotics Antipsychotics Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone First generation antipsychotic Antipsychotics Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
- Primary Outcome Measures
Name Time Method % responders to first generation antipsychotics vs. % responders to second generation antipsychotics 8-12 weeks
- Secondary Outcome Measures
Name Time Method % of treatment abandon and respective causes 8-12 weeks
Trial Locations
- Locations (1)
Instituto de Psiquiatria - Hospital das Clinicas FMUSP
🇧🇷Sao Paulo, Brazil